Exchange: NASDAQ·Updated 04:16 PM EST
ZVRA logo

ZVRA Zevra Therapeutics Inc

$8.74
$0.31
(3.42%)
Today
Closed $8.76
$0.02
(0.23%)
After Hours
Reported EarningsNov 3
Mkt Cap$539.71M
Vol1.15M

About ZVRA

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
45

Neutral Sentiment

How do you feel about ZVRA?

ProphetofProfits20
$ZVRA Thank you Neil and Tamara for YET another failure. 1st - The infamous ACER deal, initially costing shareholders about 93 million and putting ZVRA back in debt. 2nd - Then writing off over 70 million last year as per that deal. 3rd - Neil securing financing to pay off that debt unfortunately he tied our SDX portfolio to that financing. 4th - Spending millions defending the lawsuit from Commave that was created from the botched financing deal. 5th - A more than 10 million share offering TO INSTITUTIONAL INVESTORS ONLY. Yes, regular shareholders were not able to participate. This offering was done as the discount price of $6.50 when the stock was over $8 a share. 6th - Settling the lawsuit for 50 million. It paid off the financing debt but cost us our SDX portfolio including Azstarys. By the way Commave flipped that portfolio shortly after for 650 million. Now add this failure. How about another round of options, warrants, and/or RSU's for officers and directors to celebrate.
1
21
DevAd
$ZVRA Shionogi acquired IntraBio specifically to build out a high-margin, global rare-disease footprint. Adding Zevra’s Miplyffa (arimoclomol) would make Shionogi the undisputed commercial leader in Niemann-Pick disease type C. Let's make this happen, Neil. 2 Billion, but would take 1.5.
18
Torn891
$ZVRA Excited to hear Neils forward looking guidance. In the past he has given us such exciting and valuable guidance as : 1. When the call will end 2. That tomorrow is Wednesday.
17
farcanal
$ZVRA post-Earnings: • HC Wainwrong maintains Buy, $26 PT. • Cantor Fitzgerald maintains Buy, $25 PT. • Cannacord maintains Buy, $20 PT. • Nurse Neil maintains his salary and freerider rewards. • Torpid Tamara & board maintain their directors fees and their pathetic lack of a meaningful shareholding in the Co.
15
farcanal
$ZVRA The current size of the sales team is “right-sized for today” while easily scalable. Hallelujah for that because I don’t think I can bear any further empire building headcount for what is largely a one product operation at present.
15
Rookie69
$ZVRA Many will hate me but Neil just needs to sell out 5x revenue plus cash = 960m or $15 a share roughly put me out of my misery please
15
ChiefTanto
$ZVRA Profitable. Debt free. Trading at 2x cash fully diluted. My account can't handle anymore shareholder value.
14
ProphetofProfits20
$ZVRA Part 2, my conclusions agree or not. Zevra has become solidly profitable. Miplyffa scripts are still growing in the US. EU would be a bonus. Not expecting a different outcome from the CHMP but would like to be surprised and get a recommendation. I believe that they should try for approval even without it because of all the real-life usage data increasing by the quarter. Miplyffa revenues increasing, expenses are under control, no debt, with cash increasing to 270 million. We also have a large 200 million tax credit on the books. As far as companies go, this is the goldilocks scenario. For a small company, it doesn't get much better quarter after quarter. As for Celiprlol, up 6 more to 72 and still a long way to go in the stage 3 trail. Won't help short term but worth keeping an eye on each quarter to see progression. Neil, please don't screw this up by buying something. Just continue working on what ZVRA has going.
14
DevAd
$ZVRA They plan to file an sNDA in Q1 2027 for MIPLYFFA in infants under 24 months. Remember that Miplyffa’s one clear label advantage over Aqneursa is the youngest patients, 2 years and up with no weight floor against Aqneursa’s 15kg. Extending below 24 months widens precisely the gap where Zevra already wins, into a segment the competitor cannot reach at all.
14
gnom
$ZVRA very few shares left for retail. Share holders are not notified when an NDA is contracted by an interested firm. Only when an offer is presented to the BOD. This price squeeze, in my opinion, is to push out remaining retail before an offer is presented. ZVRA will then be forced to accept or Tutes could threaten to bail and kill the stock price. With only one main marketable product, ZVRA is in a box. A BO will happen. This could be the last shake out. Hold on........
9
Kittinvestments
$ZVRA currently trading at 2x cash positions 🤣 The manipulation is so big, it is ridiculous!
13
MikeyNJ
$ZVRA My gut tells me they get a limited approval in Europe. I believe the Real World data is supportive evidence which was not included in the original application and 90+% of novel drugs approved in the EU have also received FDA approval. We shall see.
13
KemPharm_rocks
$ZVRA Biggest takeaway from the EC: WE ARE NOT BUYING ANYTHING or ANYONE! STOP ASKING! WE MIGHT BE FOR SALE THOUGH!
13
KemPharm_rocks
$ZVRA Obviously this is an amazing potential win for parents whose children are diagnosed at infancy. Also, from a pure business perspective, the bigger strategic value of reaching the early-infantile NPC market is the ability to offer earlier intervention (potentially slowing progression before major neurological damage) and a broader label.
13
DevAd
$ZVRA I was concerned that IntraBio (Aqneursa) would take our market share, especially after being acquired by deep-pocketed Japanese pharma, but diving deeper revealed that both drugs serve clear, distinct purposes. Aqneursa is tailored for patients seeking rapid symptom relief, whereas Miplyffa focuses on long-term disease modification. While using both concurrently could benefit the combined patient base, insurers refuse to cover dual-therapy costs. Our key advantage lies in treating patients at early diagnosis, whereas Aqneursa must wait until they reach 15 kg.
13
ZVRA100
$ZVRA hopefully we wake up on Monday to a buyout at $20. Good night everyone. Has been a terrible day.
12
jo100toyou
$ZVRA My only hope is the Nurse Neil can sell the company at a good price. I have never thought he has the knowledge, but I thought he is a better PR person than Travis. I am wrong!!! Sell the company, Nurse Neil!
12
MandoTrades
$ZVRA It's hilarious how little this means, what a dip. This drug works, makes a ton of money in the US... but, cross the pond and it's bad, LOL.
12
intowits
$ZVRA Per AI: "Historical regulatory data reveals a clear & profound trend: orphan drugs consistently make up the vast majority of medicines undergoing the CHMP re-exam process." "The Rare Disease Majority (86%):" " A landmark regulatory study analyzing CHMP re-exams over a multi-year period found that 6 out of 7 (86%) of the new medicinal products that successfully reversed a negative opinion during a re-examination were ORPHAN DRUGS for rare diseases." "During that same evaluated timeframe, orphan drugs accounted for only about 15% (32 out of 219) of all initial MAAs. This confirms that orphan drugs seek re-examination at a vastly higher rate than standard therapies. Refining Indications: When a trial's data isn't robust enough to support a broad initial indication, the EMA Re-examination Process allows different rapporteurs to step in. This gives companies a mechanism to narrow or alter the therapeutic indication to fit a specific, highly responsive subset of rare disease patients.
12
MikeyNJ
$ZVRA Don't try to make any sense out of this one. It's an exercise in futility. Any person with a modicum of business sense would look at the valuation and question how low it is. How could a company with $300M in cash, zero debt, and a drug on the market with 2027 estimated sales between $177M and $200M, with an estimated profit of approximately $1.10/share, be trading at a $580M market cap? The stock continues to trade at a forward looking P/E of 9. Subtract the cash, and it is trading at 1.5 times 2027 sales. Common sense would indicate that there would be takeover interest here for at least $1B. Yet, it continues to trade at an inexplicable low valuation. Something smells rotten in Boston.
12

Advertisement|Remove ads.